Sanofi
Sanofi’s Dupixent improves skin clearance in paediatric atopic dermatitis
August 7, 2019Research and Development Dupixent, Sanofi, atopic dermatitis, pharma
As the therapy secured approval in Europe for treatment of adolescent patients with moderate-to-severe atopic dermatitis, Sanofi has revealed new …
Sanofi’s Dupixent extended in Europe to cover adolescents in atopic dermatitis
August 6, 2019Manufacturing and Production, Sales and Marketing EU, Europe, Sanofi, atopic dermatits, pharma
Sanofi has announced that European Commission (EC) has chosen to extend the marketing approval of its interleukin-4 (IL-4) and interleukin-13 …
Sanofi ends partnership with Lexicon after release of Phase 3 data
July 29, 2019Sales and Marketing Lexicon, Sanofi, Zynquista, diabetes, pharma
French firm Sanofi has said it is ending its partnership with Texas-based firm Lexicon Pharmaceuticals over the development of diabetes …
Libtayo becomes first EU-approved therapy for advanced cutaneous squamous cell carcinoma
July 2, 2019Manufacturing and Production, Sales and Marketing Europe, Libtayo, Regeneron, Sanofi, carcinoma, pharma
The European Commission has revealed that it has decided to award approval, albeit conditionally, to Sanofi and Regeneron’s Libtayo (cemiplimab) …
FDA approves Dupixent for chronic rhinosinusitis with nasal polyposis
June 27, 2019Sales and Marketing Dupixent, FDA, Sanofi, US, pharma, rhinosinusitis
Regeneron Pharmaceuticals and Sanofi have revealed that their dual IL-4 and IL-13 inhibitor Dupixent (dupilumab) has secured FDA approval in …
Sanofi to axe 466 R&D positions in Germany and France
June 21, 2019Medical Communications, Research and Development, Sales and Marketing Sanofi, pharma
Sanofi has announced that plans to reorganise its research and development operations will result in the losses of 466 jobs …
Top Ten most popular articles on Pharmafile.com this week!
June 14, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Astellas, GSK, J&J, JJ, Otsuka, Pfizer, Purdue, Sanofi, Vertex, pharma
Pfizer supressed research showing their arthritis drug Enbrel reduced the risk of Alzheimer’s. This was the big revelation this week! …
Sanofi’s Soliqua proves superior to GLP-1 RA therapies in reducing blood sugar levels
June 10, 2019Research and Development, Sales and Marketing Sanofi, Soliqua, diabetes, pharma, type 2 diabetes
Sanofi has stepped up at the American Diabetes Association (ADA) 79th Scientific Sessions in San Francisco, revealing new data which …
Novartis Pharma head to become new Sanofi CEO
June 7, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Novartis, Paul Hudson, Sanofi, appointment, olivier brandicourt, pharma
French drugmaker Sanofi has revealed that its CEO Olivier Brandicourt is to retire from the role, to be replaced with …
Isatuximab improves on standard of care treatments for multiple myeloma
June 3, 2019Sales and Marketing Cancer, Immunogen, Sanofi, isatuximab, multiple myeloma, pharma
Sanofi and ImmunoGen’s isatuximab combination therapy prolonged progression free survival by five months compared to standard of care treatments in …
Dr Dietmar Berger returns to big pharma
May 31, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Atara, R&D, Sanofi, oncology, pharma, research
Industry veteran Dr Dietmar Berger has joined Sanofi as the company’s new Global Head of Development. Dr Berger joins the …
Sanofi’s Dupixent approved in Europe for severe asthma maintenance
May 9, 2019Sales and Marketing Dupixent, EU, Europe, Sanofi, asthma, pharma
Sanofi has revealed that its interleukin-4 and interleukin-13 (IL-4 and IL-13) inhibitor Dupixent (dupilumab) has been awarded marketing approval by …
Sanofi’s Dengvaxia becomes first FDA-approved dengue vaccine, but with caveats…
May 2, 2019Sales and Marketing FDA, Sanofi, dengue, dengvaxia, pharma
Sanofi has announced that the FDA has granted authorisation to its tetravalent vaccine Dengvaxia for prevention of dengue disease originating …
Sanofi and Lexicon’s Zynquista scores EU approval for type 1 diabetes patients
April 29, 2019Sales and Marketing Lexicon, Sanofi, Type 1 diabetes, Zynquista, diabetes, pharma
The European Commission has authorised the use of Sanofi and Lexicon’s Zynquista (sotagliflozin) in Europe in the treatment of specific …
Alnylam and Sanofi close research phase of 2014’s $700m RNAi rare disease partnership
April 8, 2019Research and Development, Sales and Marketing Alnylam, Genzyme, Sanofi, pharma, rare disease
Alnylam and Sanofi have announced their intention to bring to an end the research and option phase of a $700 …
Latest content
Aiforia deal to expand access to pathology AI
SMC accepts atogepant for acute migraine treatment in Scotland
New CCO Ogburn joins Cori Clinical
